Journals / Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi / 2023 / Cilt: 18 Sayı: 1

Our Radiotherapy Results in Patients with Primary Non-Small Cell Lung Cancer with Brain Metastases

Primeri Küçük Hücreli Dışı Akciğer Kanseri Olan Beyin Metastazlı Hastalarda Radyoterapi Sonuçlarımız

Pages
1–8
Publication Date
2023-03-16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Age, gender, the number of brain metastases the number of brain metastases brain metastasis, surgery, ECOG/PS, chemotherapy, radiotherapy and visceral organ metastasis were found to be factors affecting survival in patients with brain metastases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Lung cancer is the most common cancer worldwide and is among the leading causes of cancer death.
📊
Key Findings & Data:Materials and Methods: This study included 99 patients with primary non-small cell lung cancer.
💡
Conclusion & Impact:Conclusion: Age, gender, the number of brain metastases the number of brain metastases brain metastasis, surgery, ECOG/PS, chemotherapy, radiotherapy and visceral organ metastasis were found to be factors affecting survival in patients with brain metastases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:akciğer kanseri · beyin metastazı · radyoterapi

Abstract

Objective: Lung cancer is the most common cancer worldwide and is among the leading causes of cancer death. The aim of this study is to examine the survival of patients who received radiotherapy for the brain metastases, whose primary is non-small cell lung cancer, and also determine the factors that are like to affect the survival and to examine the results of radiotherapy in these patients as well. Materials and Methods: This study included 99 patients with primary non-small cell lung cancer. All patients with brain metastases received radiotherapy. The patients were grouped and compared according to the number of brain metastases, whether surgery was performed for brain metastasis, gender, pathology and stage of the primary focus, visceral organ involvement, and ECOG performance status after brain metastasis developed. Results: The change in survival rate according to the number of brain metastases at the time of diagnosis was found statistically significant (p<0.01). When the stages and survival of the patients at the time of diagnosis were compared, it was statistically significant (p<0.01). Similarly, the differences among the ECOG/PS status was also statistically significant (p<0.01). When patients with visceral organ metastases were divided into two groups as to groups as dead and alive, it was observed that the number of exitus that most of the patients were lost to their metastatic state (p<0.001). Conclusion: Age, gender, the number of brain metastases the number of brain metastases brain metastasis, surgery, ECOG/PS, chemotherapy, radiotherapy and visceral organ metastasis were found to be factors affecting survival in patients with brain metastases.

Özet

Amaç: Akciğer kanseri, dünya çapında en sık görülen kanserdir ve kanser ölümlerinin önde gelen nedenleri arasındadır. Bu çalışmada amaç; beyin metastazları nedeniyle radyoterapi alan, primeri küçük hücreli dışı akciğer kanseri olan hastalarda radyoterapi etkilerini, sağkalımları ve sağkalımı etkileyebilecek faktörleri araştırmaktır. Gereç ve Yöntemler: Bu çalışmaya primer küçük hücreli dışı akciğer kanserli 99 hasta dâhil edildi. Beyin metastazı olan tüm hastalara radyoterapi uygulandı. Hastalar, beyin metastazı sayısı, beyin metastazı için ameliyat yapılıp yapılmadığı, cinsiyet, patoloji ve primer odak evresi, viseral organ tutulumu ve beyin metastazı sonrası ECOG performans durumuna göre gruplara ayrıldı ve gruplar kendi içinde karşılaştırıldı. Bulgular: Tanı anındaki beyin metastaz sayısına göre sağkalım oranındaki değişim istatistiksel olarak anlamlı bulundu (p<0.01). Hastaların tanı anındaki evresine göre sağkalım karşılaştırıldığında istatistiksel olarak anlamlı fark bulundu (p<0.01). Benzer şekilde ECOG/PS durumuna göre sağ kalım oranındaki değişim istatistiki olarak anlamlı bulundu (p<0.01). Visseral organ metastazı olan hastalar kendi aralarında yaşayanlar ve yaşamayanlar olarak iki gruba ayrıldığında yaşamayan hasta sayısının yüksek olduğu gözlendi (p<0.001). Sonuç: Beyin metastazı gelişmiş hastalarda; yaş, cinsiyet, beyin metastaz sayısı, cerrahi, ECOG/PS, kemoterapi, radyoterapi ve viseral organ metastazının sağkalımı etkileyen faktörler olduğu bulunmuştur.

🔖

Cite This Article

KARACA, F., MENTEŞ, S., ARSLAN, A., SARAÇ, M. E., KESKİN, S., ÇİL, T. (2023). Our Radiotherapy Results in Patients with Primary Non-Small Cell Lung Cancer with Brain Metastases. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, Cilt: 18 Sayı: 1, 1–8. https://ajindex.com/articles/908408

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011,
  2. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/archive/csr/1975_2011/
  3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
  4. Plönes T, Dango S, Brugger W, Ludwig C, Stoelben E. Potentially curative surgical therapy in oligometastatic nonsmall cell lung cancer. Dtsch Med Wochenschr. 2014;139(11):538–542.
  5. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82:197–203.
  6. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–2872.
  7. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31:895–902.
  8. Davey P, Hoegler D, Ennis M, Smith J. A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol. 2008;88:173–176.
  9. Grossi F, Kubota K, Cappuzzo F, d Mrinis F, Gridelli C, Aita M et al. Future scenarios for the treatment of advanced non-small cell lung cancer: Focus on taxane-containing regimens. Oncologist. 2010;15:1102–1112.
  10. Sundstrom JT, Minn H, Lertola KK, Nordman E. Prognosis of patients treated for intracranial metastase with whole-brain irradiation. Ann Med. 1998;30:296-299.
  11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-754.
  12. Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat.2003;2:111-115.
  13. Arbit E, Wronski M, Burt M, Galicich JH. The treatment of patients with recurrent brain metastases: A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer. 1995;76:765-773.
  14. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Huntingt). 1999;13:941. Edge SB, Byrd DR, Compton CC, Fr